Download Free Sample
Buy Now
Market Outlook
The global biosimilars market, valued at USD 28.0 billion in 2025, is projected to reach USD 32.3 billion in 2026 and USD 130.1 billion by 2035, representing a CAGR of 16.7% during the forecast period 2026 to 2035.
See What’s in the Full Report - Request Your Complimentary Insights!
Market Report: Key Takeaways
Market Size & Trends
- In terms of drug class, monoclonal antibodies hold the highest share of the market.
- With respect to therapeutic area, oncological disorders dominate (~40%) the current market.
- Based on the type of manufacturer, in-house developers capture the largest share of the market, and this trend is unlikely to change in the future.
- With respect to distribution channel, hospital pharmacies dominate (nearly 45%) the current market.
- In terms of geographical regions, currently, Europe holds the highest market share (over 50%).
Key Market Statistics
- Market Size in 2026: $32.3 Billion
- Estimated Market Size in 2035: $130.1 Billion
- CAGR (2026-2035): 16.7%
- Europe: Largest market in 2026
- North America: Fastest growing region
Market Introduction
The biosimilars market growth over the next decade is expected to be driven by increased biologics patent expiry, leading to the development of alternative biosimilars that are clinically similar to their reference biologics.
In recent years, the biologics industry has witnessed robust expansion, which is primarily due to its enhanced effectiveness in treating chronic disorders. However, the high costs associated with biologics pose significant economic and healthcare burdens. As demand for biologics continues to rise, the developers are seeking novel strategies to develop more affordable biologic products with similar safety and efficacy profiles in order to maximize returns on their investments. Amidst patent cliffs, shrinking drug pipelines, and pressure to reduce treatment costs, an unprecedented position of biosimilars on the market of biopharmaceuticals is witnessed.
The most recent advancement in the biologics and biosimilars market has been the launch of GLP-1 agonist liraglutide biosimilar in the US and UK in 2025. Semaglutide, which holds the largest share of the GLP-1 market, is expected to see first biosimilar launch in 2026. Sandoz has filed for approval for its semaglutide biosimilar in Canada. In the past few years, the domain has witnessed increased investment and collaborative efforts by the biosimilar developers. Further, regulatory advancements, streamlined approval procedures, and interchangeability studies have supported the biosimilars development, such as oncology biosimilars.
As the market for biosimilars continues to grow as an economical choice, the in-house development and outsourcing services operations are expected to increase correspondingly. This trend is poised to present attractive growth opportunities for biosimilar developers.
Unlock Deeper Insights – Schedule Your Personalized Workshop Today!
Market Segmentation
Based on the research, we have segmented the biosimilars market report into drug class, therapeutic area, type of manufacturer, distribution channel, geographical regions, and leading players.
By Drug Class
- Monoclonal Antibodies
- Proteins
- Peptides
- Others
By Therapeutic Area
- Oncological Disorders
- Autoimmune and Inflammatory Disorders
- Hematological Disorders
- Metabolic Disorders
- Other Disorders
By Type of Manufacturer
- Contract Manufacturers
- In-house Developers
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Geographical Regions
- North America
- US
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- New Zealand
- Rest of the Asia-Pacific
- Middle East & Africa
- Egypt
- Iran
- Iraq
- Israel
- Saudi Arabia
- South Africa
- United Arab Emirates
- Latin America
- Argentina
- Brazil
Want Information on Specific Region / Segment?
Key Insights
Biosimilars Pipeline Overview: Over 440 Biosimilars are Approved across the Globe
- The market landscape features the presence of more than 900 biosimilars targeting a wide range of chronic disorders.
- It is worth highlighting that more than 170 biosimilars are currently being evaluated in different phases of clinical trials.
- Further, over 245 biosimilars are currently in the preclinical and discovery stage of development, indicating rising need for these therapies and substantial research and development activity.
Global Biosimilars Developer’s Landscape: Asia-Pacific Emerges as a Key Hub
- The market landscape features the presence of more than 170 players, with different company sizes including, very large, large, mid-sized, small and very small. Close to 35% of these biosimilar developers were established pre-1990, demonstrating the presence of well-established stakeholders in the biosimilars domain.
- Additionally, over 60% of the biosimilar companies are based in Asia-Pacific, followed by Europe, North America and the rest of the world. Further, within Asia-Pacific, India and China emerged as the hub for biosimilar development.
Key Market Drivers: Impending Patent Expiry of Blockbuster Biologics and Uptake of Biosimilars to Drive Market Growth
The biosimilars market size is estimated to be worth USD 32.3 billion in 2026. The market growth is expected to grow at a CAGR of 16.7%, driven by the patent expiry of blockbuster biologics and increasing demand for biosimilars as a cost-effective alternative. It is worth noting that several biologics are anticipated to fall off the patent cliff in the near future.
Positive biosimilar market trends have been noticed up lately, reflected by sales data published by the biosimilar developers. For instance, in the first half of 2025, Sandoz biosimilars achieved sales of USD 1,496 million, a 12% increase in constant currency, driven by robust growth in Europe and international markets.
Recent Developments in Biosimilars Industry
- In February 2026, the USFDA accepted the license application of Dr. Reddy’s Orencia biosimilar for the treatment of rheumatoid arthritis.
- In January 2026, Samsung Epis announced the addition of six new biosimilars to its pipeline for the treatment of various disorders, including immunology and oncology.
- In December 2025, the USFDA approved denosumab biosimilars Conexxence and Bomyntra (developed by Fresenius Kabi) for all indications including osteoporosis and bone metastases.
- In October 2025, Hikma and Celltrion partnered to broaden access to six biosimilar treatments across the Middle East and North Africa (MENA) region. Under this partnership, Hikma holds exclusive commercialization rights in MENA while Celltrion handles development, manufacturing, and supply of the biosimilars.
- In June 2025, Alvotech and Dr. Reddy’s entered into a collaboration in order to co-develop a biosimilar candidate.
Industry Experts
The biosimilars market report includes transcripts of the following other third-party discussions:
- Senior VP and Head of Therapeutic Area Biosimilars, Large Company in the UK
- Professor, University, Netherlands
- Vice Chancellor, University, India
The market for biosimilars has a transformative future and is likely to remain progressive in the future.
Dr. Stefan Glombitza (CEO of Formycon) stated that, “In the evolving landscape of biologics, biosimilars have emerged from a regulatory concept to a critical solution addressing both patient access and healthcare sustainability. With the growing pressures on global healthcare systems and the imminent patent expiries of many biologics, the opportunity to provide effective, affordable treatment options has never been clearer. At Formycon, we are not just developing biosimilars, we are committed to leading this transformation, partnering with regulators and stakeholders to ensure these therapies reach patients worldwide and improve lives.”
Market Share Insights
Which Drug Class Account for the Largest Share of Biosimilars Industry?
- The global market is categorized into different drug classes, such as monoclonal antibodies, proteins, peptides and others.
- As per our biosimilars market analysis, currently, the monoclonal antibodies market segment captures maximum share and is expected to remain dominant during the forecast period.
- It is worth highlighting that peptides therapeutics market segment is likely to have highest biosimilars market growth during the forecast period. There are over 70 peptide-based therapies available worldwide, and an increase in prescription-based peptide drugs is anticipated as many biologics approach potential patent expiry, leading to a rise in generic versions.
Regional Analysis: Which Regions are Showing the Fastest Growth in Biosimilars Industry?
Europe: Dominating the Market by Securing Highest Share
- Europe accounts for more than 50% of the biosimilars market share. This can be attributed to the aging population that drives increased demand for biologic treatments for chronic conditions like rheumatoid arthritis, cancer, and autoimmune diseases, boosting the adoption of biosimilars.
- This growth is fueled by proactive government policies promoting biosimilar adoption, stringent regulatory guidelines from the European Medicines Agency (EMA), and increasing investments in research and development.
- Countries such as France, Germany, Italy, Spain, and the UK are leading contributors, benefiting from heightened disease burden and patent expiries of major biologics. In 2025, the European Medicines Agency recommended approval for nine biosimilars, including seven denosumab, one golimumab, and one ustekinumab biosimilar, further supporting biosimilar uptake in these markets.
US Biosimilars Market
- In the US, the rapid expansion of biosimilars market size is driven by several key factors, including a supportive regulatory environment established by the USFDA, which has streamlined the approval process for biosimilars and enhanced market access.
- Additionally, collaboration among major pharmaceutical companies, such as Amgen, Biocon, Viatris, and Samsung Bioepis is accelerating biosimilar development and adoption in the US. Government policies, including the Inflation Reduction Act (IRA), promote biosimilar use, especially in Medicare. Payer demand and pharmacy benefit manager (PBM) incentives further support market growth.
- The shifting distribution of biosimilars from hospitals to retail and specialty pharmacies is also fostering greater patient accessibility. Notably, the launch of interchangeable biosimilars like those for Humira and Stelara is expected to significantly increase adoption.
- This growth is underpinned by ongoing innovation related to biosimilar technology, increased physician and patient acceptance, and strategic partnerships among stakeholders facilitating broader biosimilar adoption across the US healthcare system.
Get an Instant Quote in 10 Minutes. Lowest Price Guaranteed
Will In-house Developers Segment Hold the Highest Share in the Future?
- As per our biosimilars market forecast, presently, majority of the market is occupied by in-house developers.
- However, the market for contract manufacturers involved in providing services for developing biosimilars is estimated to grow at a higher annualized rate (CAGR) of 18.1%, till 2035.
Biosimilars Market: Report Attributes
| Key Report Attribute | Details | |
| Historical Trend | Since 2020 | |
| Forecast Period | Till 2035 | |
| Market Size 2026 | USD 32.3 Billion | |
| Market Size 2035 | USD 130.1 Billion | |
| CAGR (Till 2035) | 16.7% | |
| Segments Covered |
|
|
| Key Players Profiled |
(A complete list of companies captured is available in the report) |
|
| PowerPoint Presentation (Complimentary) | Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
